Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

13 Jun 2003

Abstract excerpt

BACKGROUND: General and site-specific DNA methylation is associated with tumor progression and resistance in several cancers, including chronic myelogenous leukemia (CML). Decitabine is a hypomethylating agent that has shown encouraging preliminary anti-CML activity. This study evaluated the activity and toxicity of decitabine in different phases of CML. METHODS: One hundred and thirty patients with CML were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12879469
DOI: 10.1002/cncr.11543

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaPMID 12879469Read ↗

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaSemantic proximity Read ↗

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.Semantic proximity Read ↗

Decitabine and its role in the treatment of hematopoietic malignanciesSemantic proximity Read ↗

Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).Semantic proximity Read ↗

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemiaSemantic proximity Read ↗

DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.Semantic proximity Read ↗

Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemiaSemantic proximity Read ↗

In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studiesSemantic proximity Read ↗

Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experienceSemantic proximity Read ↗

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid LeukemiaSemantic proximity Read ↗

Decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

DecitabineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.